Related Experiment Video
Updated: Jun 11, 2025
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Immune Checkpoint Inhibitor Therapy for Metastatic Melanoma: What Should We Focus on to Improve the Clinical
Sultana Mehbuba Hossain1, Kevin Ly1, Yih Jian Sung1
1Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9016, New Zealand.
Abstract:
Immune checkpoint inhibitors (ICIs) have transformed cancer treatment by enhancing anti-tumour immune responses, demonstrating significant efficacy in various malignancies, including melanoma. However, over 50% of patients experience limited or no response to ICI therapy. Resistance to ICIs is influenced by a complex interplay of tumour intrinsic and extrinsic factors. This review summarizes current ICIs for melanoma and the factors involved in resistance to the treatment. We also discuss emerging evidence that the microbiota can impact ICI treatment outcomes by modulating tumour biology and anti-tumour immune function. Furthermore, microbiota profiles may offer a non-invasive method for predicting ICI response. Therefore, future research into microbiota manipulation could provide cost-effective strategies to enhance ICI efficacy and improve outcomes for melanoma patients.
Insights
Immune checkpoint inhibitors (ICIs) show promise in melanoma treatment but often face resistance. Emerging research suggests the gut microbiota influences ICI efficacy and may predict patient response.
Area of Science:
- Oncology
- Immunology
- Microbiome Research
Background:
- Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, particularly for melanoma.
- A significant challenge remains: over 50% of patients do not respond to ICI treatment.
- Resistance to ICIs is multifactorial, involving complex tumor-intrinsic and extrinsic elements.
Purpose of the Study:
- To review current immune checkpoint inhibitors (ICIs) used for melanoma treatment.
- To summarize the known factors contributing to resistance against ICIs.
- To explore the emerging role of the microbiota in modulating ICI therapy outcomes.
Main Methods:
- Literature review of current immune checkpoint inhibitors (ICIs) for melanoma.
- Analysis of factors influencing resistance to ICI therapy.
- Synthesis of evidence on microbiota's impact on tumor biology and immune function.
Main Results:
- ICIs are effective in various cancers, but resistance is common in melanoma.
- Tumor-intrinsic and extrinsic factors contribute to ICI resistance.
- The microbiota influences anti-tumor immunity and may predict ICI response.
Conclusions:
- The microbiota's role in modulating ICI efficacy and predicting response is a promising area.
- Targeting the microbiota could offer novel strategies to overcome ICI resistance in melanoma.
- Further research into microbiota manipulation may lead to improved treatment outcomes for melanoma patients.
